Several RCTs have demonstrated that LDLT macrolides can improve symptoms and quality of life in patients with CRS, particularly those with CRSsNP, normal total IgE levels, and corticosteroid resistance [109]. The gene discussed is IGHE; the disease is congenital rubella syndrome.